E

Edwards Lifesciences

Develops transcatheter heart valves and devices

Senior Marketing Manager - Transcatheter Mitral and Tricuspid Therapies

Full-Time
CA$125k - CA$177k/yr+ Performance-based incentives
Expert
Bachelor's, Master's
Mississauga, ON, Canada
In Person
Growth & MarketingProduct Marketing

About the job

Requirements
  • A Bachelor’s degree or equivalent in a related field and 10 years of related experience in medical device sales, marketing, structural heart, cardiovascular, or healthcare industry, or a Master’s degree or equivalent in a related field and 8 years of related experience in those areas.
  • Proven successful project management skills, an entrepreneurial mindset, and a hands-on work ethic.
  • Excellent documentation, communication, interpersonal relationship, negotiating, and relationship management skills, with the ability to drive achievement of objectives.
  • Expert-level understanding of marketing concepts and principles as applied to high-growth, clinically complex therapies.
  • Extensive understanding of broad market research designs and the ability to develop market research programs in coordination with the global Voice of Customer manager.
  • Ability to forecast product lines based on market development, sales trends, competition, and changing market dynamics.
  • Ability to assess and understand market share, pricing, average selling prices, and competitive dynamics.
  • Strong clinical knowledge of mitral and tricuspid valve disease, transcatheter structural heart therapies, heart team decision-making, patient referral pathways, and purchasing and adoption processes within complex healthcare networks.
  • Ability to translate complex clinical evidence, procedural innovation, and unmet patient needs into market development strategies for mitral and tricuspid therapies.
  • Ability to interact professionally with all organizational levels and escalate issues appropriately.
  • Ability to manage competing priorities in a fast-paced environment.
  • Proven expertise in Microsoft Office Suite.
  • Ability to comply with company rules and requirements, including Environmental Health and Safety rules, injury prevention, environmental protection, and pollution prevention responsibilities.
Responsibilities
  • Develop and execute the annual product marketing plan for the Transcatheter Mitral and Tricuspid Therapies business unit.
  • Develop and lead execution of comprehensive marketing plans, campaigns, strategies, tactics, launch readiness plans, and market development initiatives for transcatheter mitral and tricuspid therapies across repair and replacement platforms.
  • Build and maintain relationships with structural heart key opinion leaders, interventional cardiologists, cardiac surgeons, echocardiographers, and other heart team stakeholders to inform launch plans, therapy adoption, and market development priorities.
  • Develop TMTT-specific marketing messages based on local and regional strategy, clinical evidence, competitive dynamics, patient pathway insights, and regulatory and legal requirements.
  • Develop strategic programs supporting commercialization, therapy awareness, referral pathway development, patient identification, and market growth for TMTT technologies.
  • Drive development and approval of marketing collateral, labeling, training materials, and clinician-facing resources through legal, medical, regulatory, and compliance review processes.
  • Lead major congress, advisory board, and key opinion leader engagement initiatives supporting therapy education, clinical evidence dissemination, and peer-to-peer learning.
  • Develop and adapt Instructions for Use, patient education materials, and therapy-specific resources required for regional approvals, commercialization, and safe adoption.
  • Lead significant process or corporate initiatives, including planning and development of internal meetings.
  • Develop TMTT marketing strategies and education sessions supporting commercial excellence, including training on products, messaging, and competition.
  • Define and build clinical, economic, and real-world evidence supporting the regional value proposition for transcatheter mitral and tricuspid therapies.
  • Develop financial and business strategies, including strategic planning, annual operating plans, and forecasting.
  • Manage budgets related to product lines, campaigns, and projects.
  • Analyze clinical, competitive, referral, and market data to assess launch impact, therapy adoption barriers, account readiness, and market growth opportunities.
  • Collaborate on and help lead cross-business-unit strategies connecting TMTT with broader structural heart priorities, including strategic account development, heart team engagement, referral pathway optimization, and customer solutions.
  • Work closely with Global and Regional Marketing teams.
  • Represent marketing leadership on projects, working with cross-functional teams, marketing peers, and leaders while managing needs and messaging for upper management.
  • Consult in project settings within the specific marketing area.

About the company

Edwards Lifesciences focuses on cardiovascular medical technologies, especially transcatheter heart valves. Its products enable repairing or replacing diseased heart valves through minimally invasive procedures rather than open-heart surgery. The company builds on a long history that began with the Starr-Edwards valve and now centers on valve therapies and related diagnostics to treat heart disease. It differentiates itself by specializing in valve technologies and transcatheter approaches, backed by a track record of clinical leadership and global reach. The goal is to improve patient outcomes by providing safer, less invasive valve treatment options for people around the world.

Company Size

10,001+

Company Stage

IPO

Headquarters

Irvine, California

Founded

1958

Get referred to Edwards Lifesciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CMS finalized expanded TAVR coverage September 10, 2026, enlarging addressable Medicare volume.
  • Q2 2026 sales rose 13.6% to $1.74 billion; management raised full-year guidance.
  • AUTUS approval and ECLIPTIS launch broaden growth beyond mature TAVR programs.

What critics are saying

  • FTC settled July 2026 JC Medical charges for $10 million and compliance oversight.
  • January 2026 injunction blocked JenaValve buyout, crippling Edwards' aortic-regurgitation acquisition strategy.
  • AtriaCure, Medtronic, and Boston Scientific attack Edwards' adjacencies; failure here destroys diversification.

What makes Edwards Lifesciences unique

  • Edwards owns SAPIEN TAVR leadership and the 2025 asymptomatic-label exclusivity.
  • AUTUS, approved October 1, 2026, creates a pediatric pulmonary-valve franchise.
  • ECLIPTIS, cleared July 2026, extends Edwards into surgical stroke-prevention during cardiac surgery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

10%

2 year growth

10%
Business Insider
Oct 2nd, 2026
Edwards Lifesciences (EW) receives a Buy from RBC Capital.

Edwards Lifesciences (EW) receives a Buy from RBC Capital. Oct. 2, 2026, 09:46 PM RBC Capital analyst Kendall Au maintained a Buy rating on Edwards Lifesciences on October 1 and set a price target of $110.00. The company's shares closed yesterday at $85.19. Au covers the Healthcare sector, focusing on stocks such as Becton Dickinson, GE Healthcare Technologies Inc, and Boston Scientific. According to TipRanks, Au has an average return of -3.6% and a 22.22% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Edwards Lifesciences with a $103.40 average price target, representing a 21.38% upside. In a report released on September 28, Leerink Partners also reiterated a Buy rating on the stock with a $101.00 price target. Based on Edwards Lifesciences' latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.74 billion and a net profit of $241.9 million. In comparison, last year the company earned a revenue of $1.53 billion and had a net profit of $329.8 million Based on the recent corporate insider activity of 110 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EW in relation to earlier this year. Most recently, in August 2026, Annette Bruls, the CVP, EMEACLA of EW sold 2,644.00 shares for a total of $237,907.12. Read More on EW:

Business Wire
Oct 1st, 2026
Edwards Lifesciences wins FDA approval for AUTUS, first surgical pulmonary valve for pediatric patients

Edwards Lifesciences has received FDA approval for the AUTUS Size-Adjustable Valve, the first surgical pulmonary valve designed specifically for paediatric patients with congenital heart disease. The valve can be expanded as a child grows through a minimally invasive transcatheter procedure, potentially reducing the need for repeat open-heart surgeries. The approval was based on a pivotal study that met its primary safety and effectiveness endpoints. All patients were free from device-related complications through 30 days, with no valve reinterventions through six months. Patients who completed one-year follow-up showed consistent outcomes with favourable valve performance. The AUTUS valve previously received FDA Breakthrough Device designation for addressing an important unmet need in paediatric cardiac care.

Yahoo Finance
Sep 8th, 2026
Edwards Lifesciences beats Q2 expectations, raises 2026 guidance despite lagging Dow by 5.7%

Edwards Lifesciences, an Irvine, California-based cardiovascular products company, has underperformed the Dow Jones Industrial Average in recent months. The stock is down 6.6% from its 52-week high of $96.29 reached on 7 July. Over the past three months, Edwards Lifesciences shares grew 2.8%, lagging the Dow's 3.5% gain. The 52-week performance shows similar underperformance, with the stock up 11.4% compared to the Dow's 17.1% increase. Despite this, the company reported strong Q2 results on 23 July, with net sales rising 13.6% year-over-year to $1.7 billion. Adjusted earnings per share of $0.78 beat Wall Street estimates. The company raised its 2026 sales growth guidance to 10-11% from 9-11% previously. Analysts maintain a "strong buy" consensus rating, with a mean price target suggesting 13.5% upside potential.

BioPharma Watch
Sep 2nd, 2026
Edwards Lifesciences to present at the Deutsche Bank Healthcare Summit.

Edwards Lifesciences to present at the Deutsche Bank Healthcare Summit. Key Takeaway: Edwards Lifesciences Corporation will present at the Deutsche Bank Healthcare Summit on September 16, 2026. CEO Bernard Zovighian and CFO Doretta Mistras will represent the company. A live webcast of the presentation will be available on their investor relations website. Market sentiment analysis. Positive factors. * Edwards Lifesciences is actively engaging with investors. * Participation in a prominent healthcare summit highlights company visibility. * CEO and CFO are presenting, indicating strong leadership presence. IRVINE, Calif.-(BUSINESS WIRE)-Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.Bernard Zovighian, chief executive officer, is scheduled to present at 10:00 a.m. ET. Doretta Mistras, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessibl Frequently asked questions. When will Edwards Lifesciences present at the summit? Edwards Lifesciences will present on September 16, 2026. Who will represent Edwards Lifesciences at the summit? CEO Bernard Zovighian and CFO Doretta Mistras will represent the company. Is there a webcast available for the presentation? Yes, a live webcast will be available on their investor relations website.

DealLawyers.com
Aug 31st, 2026
Antitrust: KKR agrees to record settlement of HSR non-compliance claims.

Antitrust: KKR agrees to record settlement of HSR non-compliance claims. August 31, 2026 Last year, DealLawyers blogged about the DOJ's decision to file a lawsuit against KKR, in which it alleged that the buyout giant engaged in multiple failures to comply with the HSR Act's pre-merger notification requirements. Last week, the parties filed a proposed settlement of that lawsuit with the SDNY. This excerpt from a White & Case memo summarizes the terms of the settlement: On Wednesday, August 26, 2026, the DOJ filed a proposed settlement requiring KKR & Co. Inc. to pay a civil penalty of $250 million, more than 20 times any prior HSR penalty obtained by the DOJ. Associate Attorney General Stanley Woodward indicated that this proposed settlement "sends a powerful message" and shows that the DOJ "is committed to vigorous enforcement of the Act." This settlement comes after the DOJ alleged in January 2025 that the private equity sponsor "repeatedly violated the HSR Act" through "systemic" violations. Key allegations in the DOJ's complaint included: - Failure to submit responsive business documents required under Item 4 of the HSR Form - Altering or removing content and pages in final Item 4 documents before submission to the FTC/DOJ as part of required HSR filings - Failure to make HSR filings before consummating reportable transactions The memo quotes a KKR spokesperson as saying that the organization determined that continuing the litigation would be a distraction to the organization & that KKR was pleased to put the litigation behind it. They also noted that their investors wouldn't feel the bite, because KKR "will be fully reimbursed by outside law firms." Yikes!!! The settlement comes on the heels of last month's settlement of the FTC's actions targeting Edwards Lifesciences & Genesis Medtech's for alleged violations of the HSR Act. At the time, the $12 million fine that the companies agreed to pay was the largest ever for failing to make an HSR filing. I guess records were made to be broken. - John Jenkins